PURPOSE: To obtain an agent for the prevention, treatment and improvement of the diseases such as a solid cancer, a keloid and an inflammation for which a suppressing action for vascularization is effective, by containing satigrel and/or aspirin or their salts as active ingredients, and high in safety and usefulness.

CONSTITUTION: This suppressing agent for vascularization contains at least one kind selected from satigrel of the formula or aspirin, or their salts as active ingredients. The clinical dosage of satigrel or aspirin is preferably 1-1000mg daily for an adult. Specifically, a preparation for the injection of satigrel is obtained e.g. by dissolving 1mg satigrel sodium, 1mg mannitol and the suitable amount of citric acid for one vial with a distilled water for injection or a saline, adjusting pH with citric acid, aseptically filtering, and then lyophilizing.